CAR-T Cell Therapy Covered by Insurance, Price Drops from $165K to $41K
China's National Healthcare Security Administration announces CAR-T cell therapy officially included in insurance coverage, reducing patient out-of-pocket costs from approximately 1.2 million yuan to under 300,000 yuan. Over 20,000 lymphoma patients expected to benefit.
Content
China's National Healthcare Security Administration officially included CAR-T cell therapy in the insurance catalog in April 2028—the first time this therapy has received insurance coverage in China.
CAR-T (Chimeric Antigen Receptor T-cell therapy) is a revolutionary treatment for hematologic system tumors like lymphoma and leukemia. Previously priced at approximately 1.2 million yuan ($165,000) per injection, leaving the vast majority of patients out of reach. After insurance inclusion, patient out-of-pocket costs will range from 150,000 to 300,000 yuan ($20,600-$41,000) depending on local medical insurance reimbursement ratios.
The NHSA stated that after multiple rounds of negotiations, relevant pharmaceutical companies agreed to reduce prices by approximately 75%, with the medical insurance fund covering approximately 60% of costs. Preliminary estimates indicate the policy will cover approximately 20,000 eligible patients, adding approximately 4 billion yuan to annual medical insurance expenditure.
Industry insiders pointed out that CAR-T therapy's inclusion in insurance is significant not only for reducing patient burdens but also for promoting the industrialization of cell therapy technology in China—more patient usage means more clinical data accumulation, which will accelerate technological iteration and indication expansion.
Boundary
This is fictional content for entertainment only.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.